Gate2Brain secures over €700,000 in CDTI Multipaís funding to advance a novel therapy against pediatric brain tumors in collaboration with India

Gate2Brain, a spin-off from IRB Barcelona, the University of Barcelona, and Sant Joan de Déu Hospital, has been awarded funding from the Centro para el Desarrollo Tecnológico Industrial (CDTI Innovación) under the Multipaís 2024 program. This financial support represents a significant milestone for Gate2Brain, reinforcing its innovative approach to drug delivery for central nervous system (CNS) diseases.

This funding is part of Spain’s Recovery, Transformation, and Resilience Plan, within the framework of the PERTE Vanguard Health initiative, which supports the development of pioneering health technologies with the potential to transform patient care. The project is also backed by the Ministry of Science and Innovation and the European Union (NextGenerationEU), reflecting the strategic importance of this research

An International Collaboration for a High-Impact Therapy

With the support of the CDTI Multipaís program, Gate2Brain is driving an international initiative with Spain and India working together to accelerate the clinical development of G2B-002. This therapy is specifically designed for the treatment of high-grade pediatric brain tumors and has already demonstrated:

• Effective blood–brain barrier penetration through Gate2Brain’s proprietary peptide shuttle technology.
• Promising anticancer activity in preclinical models.
• Good tolerability in early studies, setting the stage for further clinical validation

This funding will allow Gate2Brain to finalize the regulatory preclinical development of G2B-002 and advance towards a clinical trial in pediatric patients with diffuse midline glioma (DMG) by the end of 2027.

Transforming Pediatric Oncology and CNS Drug Delivery

Gate2Brain’s groundbreaking peptide-based platform represents a paradigm shift in noninvasive and efficient drug transport across the blood–brain barrier, a major challenge in CNS drug development. While the initial focus is on pediatric brain tumors, this technology holds significant potential for broader applications in the treatment of other CNS diseases.

This project is funded by the Centro para el Desarrollo Tecnológico Industrial (CDTI Innovación) and supported by the Ministry of Science and Innovation, the Recovery, Transformation, and Resilience Plan, and the European Union (NextGenerationEU).